The efficacy of Yiqi Huoxue therapy for chronic heart failure
A meta-analysis in accordance with PRISMA guideline

Miao Zhang, PhD\textsuperscript{a,b} \textsuperscript{1}, Ming-Yue Sun, PhD\textsuperscript{c}, Hui-Jun Yin, PhD\textsuperscript{d}, Zheng-Zhi Wu, PhD\textsuperscript{d}, Yu Jin, PhD\textsuperscript{d}, Ma Min, PhD\textsuperscript{d}, Feng-Qin Xu, PhD\textsuperscript{d,}\textsuperscript{*}

Abstract

Background: Chronic heart failure (CHF) is the final destination of most cardiovascular diseases and the most important cause of death. The main clinical manifestations were pulmonary congestion and decreased cardiac output. The purpose of this systematic review is to evaluate the effectiveness of Yiqi Huoxue therapy on CHF.

Methods: Seven electronic databases were searched to identify randomized controlled trials of Yiqi Huoxue (YQHX) method for CHF until April 30, 2020. The quality assessment of the included trials was performed by employing the Cochrane Risk of Bias tool and Jadad scale.

Results: Nineteen randomized controlled trials were included in our review. Most of the included trials were considered as low quality. The aggregated results suggested that experimental group with YQHX therapy got better effect in increasing overall response rate (risk ratio, RR = 1.21, 95% confidence interval, CI 1.15–1.27), traditional Chinese medicine (TCM) syndrome response rate (RR = 1.26, 95% CI 1.17–1.36), 6-minute walk test (RR = 2.14, 95% CI 1.05–3.22), left ventricular ejection fraction (RR = 0.97, 95% CI 0.60–1.34), and stroke volume (standardized mean difference, SMD = 0.94, 95% CI 0.23–1.56), and in lowering the TCM syndrome scores (SMD = –0.78, 95% CI –0.91 to –0.64), Minnesota Living with Heart Failure questionnaire (SMD = –1.01, 95% CI –1.56 to –0.45), 6-month readmission rate (RR = 0.50, 95% CI 0.28–0.89), B-type natriuretic peptide (SMD = –0.89, 95% CI –1.52 to –0.25), NT-proBNP (SMD = –2.07, 95% CI –3.34 to –0.08), and C-reactive protein (SMD = –2.04, 95% CI –4.12 to –0.67) as compared to using conventional Western medicine alone. There were no significant differences found in left ventricular end diastolic diameter and E/E’ between experimental groups and control groups. Moreover, the included sample capacity is small and the trials are all in Chinese. Quality of the evidence for outcomes were “low” and “very low” according to the GRADE assessment.

Conclusion: YQHX is a valid complementary and alternative therapy in the management of CHF, especially in improving overall response rate, TCM syndrome response rate, 6-minute walk test, left ventricular ejection fraction, and stroke volume and in decreasing TCM syndrome scores, Minnesota Living with Heart Failure questionnaire, 6-month readmission rate, B-type natriuretic peptide, NT-proBNP, and C-reactive protein levels. Hence, YQHX is a relatively effective and safe therapy for CHF patients, which can be popularized and applied in the clinic. More long-term follow-up studies are still needed to substantiate and confirm the current findings.

Abbreviations: 6MRR = 6-month Readmission rate, 6MWT = 6-minute walk test, BNP = B-type natriuretic peptide, CHF = chronic heart failure, CI = confidence interval, CRP = C-reactive protein, CWM = conventional Western medicine, GCRNDTCM = Guidelines of Clinical Research of New Drugs of Traditional Chinese Medicine, LVEDD = left ventricular end diastolic diameter, LVEF = left ventricular ejection fraction, MLHFQ = Minnesota Living with Heart Failure questionnaire, ORR = overall response rate, RCT = randomized controlled trial, RR = risk ratio, SMD = standardized mean difference, SV = stroke volume, TCM = traditional Chinese medicine, TCMSRR = TCM syndrome response rate, TCMS = TCM syndrome scores, YQHX = Yiqi Huoxue therapy.

Keywords: chronic heart failure, meta-analysis, traditional Chinese medicine, Yiqi Huoxue

MZ and MS contributed equally to this work.

This work was supported by a grant from the National Natural Science Foundation of China (grant number: 82104770), National Science Foundation of Guangdong Province (grant number: 2022A1515011456), and grants to Feng-Qin Xu from National Key R&D Program of China (2017YFC1700301). The authors have no conflicts of interest to disclose.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

The ethical approval was not necessary because this article is a review article that was based on others’ research. No human body and animal experiments were involved.

\* Correspondence: Feng-Qin Xu, Department of Cardiovascular Disease, Beijing Xiyuan Hospital, China Academy of Chinese Medical Sciences, Building Xingyuan, No. 1 Xiyuan Caochang, Beijing 100091, China (e-mail: Dr.xufengqin@outlook.com).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Zhang M, Sun M-Y, Yin H-J, Wu Z-Z, Jin Y, Min M, Xu F-Q. The efficacy of Yiqi Huoxue therapy for chronic heart failure: A meta-analysis in accordance with PRISMA guideline. Medicine 2022;101:34(e30082). Received: 3 November 2021 / Received in final form: 7 June 2022 / Accepted: 28 June 2022 http://dx.doi.org/10.1097/MD.0000000000030082
1. Introduction

Chronic heart failure (CHF) is a complex clinical syndrome characterized by insufficient blood perfusion of tissues and organs, abnormal distribution of peripheral blood flow, and activation of neuroendocrine, which is caused by the impairment of ejection function or ventricular filling due to the abnormality of heart function or structure. The incidence rate of CHF increases year by year. The disease seriously affects the daily life of patients, reduces the quality of life of patients, and even threatens the safety of patients. CHF is characterized by chest distress, wheezing, and paroxysmal nocturnal dyspnea. The specific clinical manifestations are palpitation, chest distress, shortness of breath, restlessness and insomnia, dry mouth, and dry tongue, often accompanied by poor urination, lower extremity edema, and cyanosis of lips with petechiae, etc. The condition is often lingering and difficult to recover, and prone to recurrent attacks. CHF is more common in the elderly. The main modern medical treatment includes general treatment (removing inducements, adjusting life style and oxygen inhalation, etc) and drug treatment. The commonly used drug treatment mainly includes cardiotonics, diuretics, blood pressure and rhythm control, vasodilators, etc. Modern medicine believes that these drugs can effectively improve myocardial contraction and reduce heart load; furthermore, it can improve hemodynamics to achieve ideal therapeutic effect. However, due to the vulnerable pathological and physiological characteristics of the elderly, adverse reactions to modern medical treatment, such as severe water and electrolyte disorders, persistent dry cough, drug poisoning, etc., may lead to serious consequences. Whereas, our findings show that the combination of traditional Chinese and Western medicine demonstrates its unique advantages and characteristics in treating CHF and avoiding the occurrence of some common adverse reactions.

Based on the basic theories of traditional Chinese medicine (TCM), CHF is equivalent to the term of “Xiong Bi” or “Chuan Zheng” or “Shui Zhong” or “Tan Yin”. The etiology and pathogenesis of CHF are related to Qi deficiency and blood stasis. In TCM, Qi is the vital life force in the body, supposedly able to be regulated by food and medicine. Qi is the concept of life-breath or vital energy function. Therefore, invigorating qi and activating circulation to remove blood stasis (Chinese name in pinyin is “Yiqi Huoxue”) is an important therapy for CHF. Yiqi Huoxue therapy (YQHX) is widely used to treat patients with CHF. A large number of animal and clinical trials have confirmed that YQHX can improve the heart function and clinical symptoms of patients with CHF by inhibiting or delaying ventricular remodeling, improving diuretic resistance, improving insulin sensitivity, regulating myocardial energy metabolism, protecting mitochondria and other mechanisms of action, so as to achieve the therapeutic effect, improve the quality of life of patients, with multi-channel and multitarget effects and little side effects. Therefore, the treatment of CHF with YQHX has high clinical application value and good prospect, which is worth promoting. However, the scientific evidence of the effect of YQHX on CHF is so far unknown or the current available information is not systematic. Therefore, we conducted a meta-analysis of clinical randomized controlled trials to evaluate the efficacy and safety of YQHX on patients with CHF.

2. Methods

2.1. Search strategy

Randomized controlled trials (RCTs) assessing the administration of YQHX Oral Chinese Herbal Medicine in the treatment for CHF were located by searching the databases CNKI, WANGFANG, VIP, Snowmed, PubMed, EMBASE, and the Cochrane Controlled Trials Register and assisted by manual retrieval. The last search was run on October 31, 2021, and case reports and small case series were excluded. No limit was placed on the language. PubMed searching strategy includes the following:

#1: Search “Medicine, Chinese Traditional”[Mesh];
#2: Search “Drugs, Chinese Herbal medicine”[Mesh];
#3: Search “Yiqi Huoxue”[Mesh];
#4: Search “Supplementing qi activating blood circulation”[Mesh];
#5: Search “chronic heart failure”[Mesh];
#6: Search “CHF”;
#7: Search (#1 OR #2 OR #3 OR #4) AND (#5 OR #6)

Above strategies were adopted for each specific database, and Chinese characters for relevant key words were used when searching Chinese databases.

2.2. Study selection

Studies were selected according to the Cochrane Handbook for Systematic Reviews of Interventions. Studies meeting the following criteria were included:

1. the studies were performed as RCTs or quasi-randomized controlled trials;
2. patients were diagnosed with CHF;
3. Jadad score[14] ≥3;
4. Western medicine was permitted to be taken according to individual symptoms;
5. YQHX formula (have classic composition Astragalus or Salvia miltiorrhiza or Codonopsis pilosula or Ginseng with clear dose) with conventional Western medicine (CWM) was used for the experimental group and CWM alone for the control group.

CWM including interventions such as oxygen uptake, rest-cure, and low-salt diet, with medicines including angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, beta-receptor blockers, diuretics, aldosterone receptor blockers, digitalis preparation, drugs belonging to ester nitrate, and others recommended in the Chinese suggestions for diagnosis and treatment of CHF. The outcomes included 6 echo-related index: overall response rate (ORR), TCM syndrome response rate (TCMSRR) by referring to the evaluation criteria of Guidelines for clinical research on Chinese new herbal medicines[15] (Table 1), TCM syndrome scores (TCMSS), Minnesota Living with Heart Failure questionnaire (MLHFQ), 6-minute walk test (6MWTT), and 6-month readmission rate (6MR); 3 serum biomarkers: levels of natriuretic peptides (BNP or NT-proBNP) and C-reactive protein (CRP); 4 cardiac function index: left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), E/E’, and stroke volume (SV). We classified “markedly effective and effective” as an effective result and “invalid and pejorative” as an ineffective result. The ORR is the ratio of effective cases to total cases.

2.2.2. Exclusion criteria. Trials that met the following criteria were excluded:

1. Yiqi Huoxue formula were used as the only treatment
2. the target population was incongruent with diagnostic criteria of CHF;
3. Data abstraction
Two authors (M.Z. and M.S.) independently screened the titles and abstracts of the achieved citations from primary searching. Full text of the articles of potential interest were downloaded for further evaluation, and those meeting inclusion criteria were included in the final review. The following contents were extracted from the included trials independently by 2 authors (M.Z. and M.S.): publication data (authors, publication year, study design, randomization, Jadad score, sample size, gender, and age); treatment protocol (YQHX formula and ingredients, Western medicine name, and dose); duration of treatment; main outcomes; adverse events; and duration of follow-up. If there were discrepancies in the process of selection, whether to include or exclude a study was resolved by a third author (H.Y.)’s opinion. Missing data were achieved through contacting authors of the original studies by telephone, email, or fax.

2.3. Study quality
The methodological quality of trials was assessed independently by 2 authors (M.Z. and M.S.) using criteria from the Cochrane Handbook for Systematic Review of Interventions. The items included random sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other bias (defined as baseline data comparability). We judged each item from 3 levels (“yes” for a low risk of bias, “no” for a high risk of bias, and “unclear” otherwise). Then the methodological quality of the trials was ranked into 3 levels: low risk of bias (all items with low risk of bias), high risk of bias (at least 1 item with high risk of bias), or unclear risk of bias (at least 1 item with an unclear domain). The discrepancies were resolved through consensus. Disagreements between the 2 authors were resolved by discussion and if needed, arbitrated by a third author (H.Y.).

2.4. Quality assessment
The methodological quality of trials was assessed independently by 2 authors (M.Z. and M.S.) using criteria from the Cochrane Handbook for Systematic Review of Interventions. The items included random sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other bias (defined as baseline data comparability). We judged each item from 3 levels (“yes” for a low risk of bias, “no” for a high risk of bias, and “unclear” otherwise). Then the methodological quality of the trials was ranked into 3 levels: low risk of bias (all items with low risk of bias), high risk of bias (at least 1 item with high risk of bias), or unclear risk of bias (at least 1 item with an unclear domain). The discrepancies were resolved through consensus. Disagreements between the 2 authors were resolved by discussion and if needed, arbitrated by a third author (H.Y.).

2.5. Statistical methods
Meta-analyses of RCTs were performed using RevMan 5.3 software from the Cochrane Collaboration for data analyses. Data were summarized by using risk ratio (RR) with 95% confidence intervals (CI) for discontinuous outcomes, or standard mean difference (SMD) with 95% CI for continuous outcomes.

| Classification | Detailed description |
|----------------|----------------------|
| Markedly effective | Clinical symptoms and signs completely disappeared, or the score ratio of clinical symptoms/TCM syndromes reduction to >70% |
| Effective | Clinical symptoms and signs were significantly reduced, with clinical symptoms/TCM syndrome score ratio reduction to 30%, but <70% |
| Invalid | Clinical symptoms and signs were partially reduced, with clinical symptoms/TCM syndrome score ratio reduction <30% |
| Pejorative | The score ratio of clinical symptoms or TCM syndromes got worse |

GCRNDCM = Guidelines of Clinical Research of New Drugs of Traditional Chinese Medicine, TCM = traditional Chinese medicine.

We assessed data by both fixed effect model and random effect model, but reported random effect analysis only if the heterogeneity was statistically significant. Statistical heterogeneity was tested by examining I², meaning that an I² > 50% indicated the possibility of statistical heterogeneity, and the value of P < .05 was regarded as statistically significant. If heterogeneity was low (I² < 50% or P > .05), the fixed effects model was used. If heterogeneity was high (I² > 50% or P < .05), the random effect model was used and subgroup analyses were conducted to determine the evidence for the different control if data were sufficient. Publication bias was assessed by funnel plot analysis if the group included more than 10 trials.

3. Results
3.1. Study selection
The search of 7 English and Chinese databases identified 296 records for further evaluation (Fig. 1). After removing duplicates, 223 potentially relevant abstracts were initially screened, and 154 were excluded for failing to meet the inclusion criteria. We retrieved and reviewed 69 full-text articles. Fifty studies were excluded due to nonrandomized, duplicate publications, suspicion of counterfeit, and failure to get available data. Nineteen RCTs of them were eligible. No dissertations and trial registrations were obtained. All studies involved patient consent, and informed consent was given. Details of the study flow are shown in Figure 1.

3.2. Study characteristics
All of the 19 included trials were conducted in China and published in Chinese language. All studies were performed in China, and the studies involved a total of 2087 patients (control group 1034 patients, experimental group 1053 patients). In addition, all studies exhibited comparable baseline patient characteristics, including age and gender (male patients 1141, female patients 946). In addition, there were no significant differences among them. The characteristics of selected studies are shown in Table 2.

3.3. Study quality
Among trials, 19 studies stated the method of the sequence generation with random number table and drawing, while none of the 19 studies reported details for sample size calculations and none was double-blind, placebo controlled study. Additionally, none mentioned allocation concealment or blinding methods. There are 15 included trials that were assessed as low risk of bias in incomplete outcome data, since outcome data was complete. Fourteen of the included trials were assessed as low risk of reporting bias, and the other 5 trials that were evaluated as unclear risk of reporting bias due to the selective reporting of predefined outcomes. Among all RCTs, the characteristics of participants in each study arm were similar at baseline (age, race, sex, and disease course), then we evaluated all of the trials at an unclear risk of other bias. The details of the risk of bias of each trial are presented in Figures 2 and 3.

3.4. Effects of the interventions
There was no report of mortality as the primary outcome measures (e.g., AMI, severity arrhythmia, revascularization). We analyzed the outcomes: 6 echo-related index: ORR (13 trials), TCMSRR (4 trials), TCMS5 (8 trials), MLHFQ (6 trials), 6MRR (2 trials), and 6MWT (8 trials); 3 serum biomarkers: BNP (9 trials), NT-proBNP (5 trials), and CRP (3 trials); 4
3.4.1. Echo-related index.

3.4.1.1. Overall response rate (ORR). Thirteen RCTs\[19,21–23,25–27,29–31,35–37\] reported ORR and found an obvious difference ($P < .00001$) between YQHX plus routine Western medicine treatment and routine Western medicine treatment alone on ORR (RR = 1.21, 95% CI 1.15–1.27, 1410 participants), which meant that YQHX plus routine Western medicine treatment was significantly better than routine Western medicine treatment in acquiring better curative effectiveness. No heterogeneity was found among the 13 trials ($I^2 = 35\%$, $P = .11$) (Fig. 4).

3.4.1.2. TCM syndrome response rate. Four RCTs [21,22,24,27] reported TCMSRR and found an obvious difference ($P < .00001$) between YQHX plus routine Western medicine treatment and routine Western medicine treatment alone on TCMSRR (RR = 1.24, 95% CI 1.12–1.37, 367 participants). The result indicated that YQHX combined with conventional Western drugs group was significantly better than conventional Western drugs group in the TCMSRR and there was significant homogeneity among the 4 trials ($I^2 = 0\%$, $P = .72$) (Fig. 5).

3.4.1.3. TCM syndrome scores. Eight RCTs\[19,23,25,26,32,33,35,37\] reported TCMS and found an obvious difference ($P < .00001$) between YQHX plus routine Western medicine treatment and routine Western medicine treatment alone on TCMS (SMD = −0.78, 95% CI −0.91 to −0.64, 969 participants). The result indicated that YQHX combined with conventional Western drugs group was significantly better than conventional Western drugs group in the TCMS and there was significant homogeneity among the 8 trials ($I^2 = 25\%$, $P = .23$) (Fig. 6).

3.4.1.4. Minnesota Living with Heart Failure questionnaire. Six RCTs\[21,25,27,30,33,37\] reported MLHFQ and found an obvious difference ($P = .0004$) between YQHX plus routine Western medicine treatment and routine Western medicine treatment alone on MLHFQ (SMD = −1.01, 95% CI −1.56 to −0.45, 809 participants). The result indicated that YQHX combined with conventional Western drugs group was significantly better than conventional Western drugs group in the MLHFQ and there was significant homogeneity among the 6 trials ($I^2 = 92\%$, $P < .00001$) (Fig. 7).

3.4.1.5. 6-Month readmission rate. Two RCTs\[26,37\] reported 6MRR and found an obvious difference ($P = .02$) between YQHX plus routine Western medicine treatment and routine Western medicine treatment alone on 6MRR (RR = 0.50, 95% CI 0.28–0.89, 200 participants). The result indicated that YQHX combined with conventional Western drugs group was significantly better than conventional Western drugs group in the 6MRR and there was significant homogeneity among the 5 trials ($I^2 = 0\%$, $P = .80$) (Fig. 8).

3.4.1.6. 6-Minute walk test. Eight RCTs\[19,22,23,26,27,31,33,37\] reported 6MWT and found an obvious difference ($P = .0001$) between YQHX plus routine Western medicine treatment and routine Western medicine treatment alone on 6MWT (RR = 2.14, 95% CI 1.05–3.22, 868 participants). The result indicated that YQHX combined with conventional Western drugs group was significantly better than conventional Western drugs group in the 6MWT and there was significant homogeneity among the 8 trials ($I^2 = 98\%$, $P < .00001$) (Fig. 9).

3.4.2. Serum biomarkers.

3.4.2.1. BNP. Nine RCTs\[20,23,24,27,29,31,32,35,36\] evaluated the effect of BNP and found BNP was significantly improved in the YQHX plus conventional drugs when compared with conventional drugs treatment alone (SMD = −0.89, 95% CI −1.52 to −0.25, 899 participants, $P = .006$). The result indicated that YQHX combined with conventional Western drugs group was
significantly better than conventional Western drugs group in the improvement of BNP, and there was significant homogeneity among the 9 trials ($I^2 = 95\%$, $P < .0001$) (Fig. 10).

3.4.2.2. NT-proBNP. Five RCTs\cite{19,21,28,29,34} reported NT-proBNP and found an obvious difference ($P = .001$) between YQHX plus routine Western medicine treatment and routine Western medicine treatment alone on NT-proBNP ($SMD = –2.07$, 95% CI $–3.34$ to $–0.08$, 473 participants). The result indicated that YQHX combined with conventional Western drugs group was significantly better than conventional Western drugs group in the NT-proBNP and there was significant homogeneity among the 5 trials ($I^2 = 97\%$, $P < .00001$) (Fig. 11).

3.4.2.3. C-reactive protein. Three RCTs\cite{20,21,27} reported CRP and found an obvious difference ($P = .006$) between YQHX plus routine Western medicine treatment and routine Western medicine treatment alone on CRP ($SMD = –2.04$, 95% CI $–4.12$ to $–0.67$, 333 participants). The result indicated that YQHX combined with conventional Western drugs group were significantly better than conventional Western drugs group in the improvement of CRP, and there was significant homogeneity among the 3 trials ($I^2 = 95\%$, $P = .001$) (Fig. 12).

Table 2

| ID (author/year) | Case (T/C) | Age (T/C) | Gender (M/F) | Control group | Intervention group | Treatment duration | Outcome | Jadad score |
|------------------|------------|-----------|--------------|---------------|--------------------|--------------------|---------|-------------|
| Liu F/2017       | 70/65      | 66.1/65.8 | 70/65        | CWM           | YQHX + CWM         | 28D                | ORR, NT-proBNP, LVEF, 6MWT, TCMSS | 3          |
| Ye Y/2014        | 60/58      | NA        | 63/55        | CWM           | YQHX + CWM         | 28D                | BNP, LVEF, CRP | 3          |
| Tang S/2018      | 60/60      | 67.32/68.32 | 69/51      | CWM           | YQHX + CWM         | 3M                | ORR, TCMSSR, NT-proBNP, LVEF, LVEDD, CRP | 3          |
| Zhou SP/2018     | 36/36      | 54/52.39  | 37/35        | CWM           | YQHX + CWM         | 14D               | ORR, TCMSSR, 6MWT | 3          |
| He P/2018        | 40/40      | 60.5/60.1 | 46/34        | CWM           | YQHX + CWM         | 3M                | TCMSSR, LVEF, 6MWT, LVEDD, SV | 3          |
| Yu G/2018        | 60/60      | 64.6/63   | 65/55        | CWM           | YQHX + CWM         | 28D               | ORR, 6MWT, TCMSSR, 6MRR | 3          |
| Wang K/2018      | 50/50      | 65.32/64.27 | 49/51      | CWM           | YQHX + CWM         | 28D                | ORR, 6MWT, TCMSSR | 3          |
| Chen WT/2017     | 60/60      | 68.37/67.52 | 64/56      | CWM           | YQHX + CWM         | 56D               | ORR, BNP, 6MWT, TCMSSR, LVEDD, E/E, MLHFQ | 4          |
| Zhang Y/2014     | 40/40      | 69.36/79.73 | 46/34      | CWM           | YQHX + CWM         | 28D               | ORR, 6MWT, TCMSSR, 6MRR | 3          |
| Wang D/2015      | 68/68      | 62.34/61.83 | 91/45      | CWM           | YQHX + CWM         | 56D               | BNP, LVEF, TCMSSR | 3          |
| Liu H/2017       | 132/122    | 73.12/72.42 | 136/118    | CWM           | YQHX + CWM         | 28D               | ORR, LVEF, LVEDD, MLHFQ | 3          |
| Yang J/2017      | 43/43      | 65.23/64.57 | 44/42      | CWM           | YQHX + CWM         | 3M                | NT-proBNP, LVEF, E/E, MLHFQ | 3          |
| Qian SU/2018     | 43/43      | 73.56/72.89 | 47/39      | CWM           | YQHX + CWM         | 30D               | ORR, BNP, LVEF, LVEF, LVEDD | 3          |
| Feng XX/2013     | 30/30      | 62.4 ± 6.7  | 34/26      | CWM           | YQHX + CWM         | 42D               | NT-proBNP, LVEF, LVEDD | 3          |
| Li HL/2019       | 36/36      | 56.67/56.43 | 41/31      | CWM           | YQHX + CWM         | 14D               | ORR, NT-proBNP, LVEF | 3          |
| Li XX/2019       | 59/59      | 67.3/67.6  | 61/57       | CWM           | YQHX + CWM         | 14D               | ORR, BNP, NT-proBNP, LVEF | 3          |
| He Pg/2019       | 48/47      | 57.73/55.49 | 58/37      | CWM           | YQHX + CWM         | 56D               | ORR, TCMSSR, BNP, LVEF, 6MWT, LVEDD, SV, MLHFQ, CRP | 4          |
| Wang XL/2019     | 80/80      | 52.85/51.59 | 83/78      | CWM           | YQHX + CWM         | 3M                | BNP, TCMSSR, 6MWT, MLHFQ | 3          |
| Zhang Y/2019     | 37/37      | 60/60      | 37/37       | CWM           | YQHX + CWM         | 30D               | ORR, BNP, LVEF, LVEDD | 4          |

6MRR = 6-month readmission rate, 6MWT = 6-minute walk test, BNP = B-type natriuretic peptide, CRP = C-reactive protein, CWM = conventional Western medicine, LVEDD = left ventricular end diastolic diameter, LVEF = left ventricular ejection fraction, MLHFQ = Minnesota Living with Heart Failure questionnaire, NA = not applicable, ORR = overall response rate, SV = stroke volume, TCMSSR = TCM syndrome response rate, TCMSS = TCM syndrome scores, YQHX = Yiqi Huoxue.

Figure 2. Risk of bias: reviewing authors’ judgments about each risk of bias item for each included study.

3.4.2.2. NT-proBNP. Five RCTs\cite{19,21,24,29,34} reported NT-proBNP and found an obvious difference ($P = .001$) between YQHX plus routine Western medicine treatment and routine Western medicine treatment alone on NT-proBNP (SMD = $–2.07$, 95% CI $–3.34$ to $–0.08$, 473 participants). The result indicated that YQHX combined with conventional Western drugs group was significantly better than conventional Western drugs group in the improvement of NT-proBNP and there was significant homogeneity among the 5 trials ($P = 97\%$, $P < .00001$) (Fig. 11).

3.4.2.3. C-reactive protein. Three RCTs\cite{20,21,27} reported CRP and found an obvious difference ($P = .006$) between YQHX plus routine Western medicine treatment and routine Western medicine treatment alone on CRP (SMD = $–2.04$, 95% CI $–4.12$ to $–0.67$, 333 participants). The result indicated that YQHX combined with conventional Western drugs group were...
Zhang et al. • Medicine (2022) 101:34

significantly better than conventional Western drugs group in the CRP and there was significant homogeneity among the 3 trials ($I^2 = 97\%, P < .00001$) (Fig. 12).

### 3.4.3. Cardiac function index.

#### 3.4.3.1. Left ventricular ejection fraction

Fourteen RCTs[19–21,24,27–36] reported LVEF and found an obvious difference ($P < .00001$) between YQHX plus routine Western medicine treatment and routine Western medicine treatment alone on LVEF (RR = 0.97, 95% CI 0.60–1.34, 1594 participants). The result indicated that YQHX combined with conventional Western drugs group was significantly better than conventional Western drugs group in the LVEF and there was significant homogeneity among the 14 trials ($I^2 = 92\%, P < .00001$) (Fig. 13).

#### 3.4.3.2. Left ventricular end diastolic diameter

Eight RCTs[21,23,24,27,30,31,34,36] reported LVEDD and found no obvious difference ($P = .33$) between YQHX plus routine Western medicine treatment and routine Western medicine treatment alone on LVEDD (SMD = -0.38, 95% CI -1.15 to 0.39, 889 participants). The result indicated that YQHX combined with conventional Western drugs group was not significantly better than conventional Western drugs group in the LVEDD and there
was significant homogeneity among the 8 trials ($I^2 = 0\%$, $P < .00001$) (Fig. 14).

### 3.4.3.3. Stroke volume.

Two RCTs\[24,27\] reported SV and found an obvious difference ($P = .02$) between YQHX plus routine Western medicine treatment and routine Western medicine treatment alone on SV (SMD = 0.94, 95% CI 0.23–1.56, 175 participants). The result indicated that YQHX combined with conventional Western drugs group was significantly better than conventional Western drugs group in the SV and there was significant homogeneity among the 2 trials ($I^2 = 80\%$, $P = .01$) (Fig. 15).

### 3.4.3.4. $E/E'$

Two RCTs\[23,28\] reported $E/E'$ and found no obvious difference ($P = .93$) between YQHX plus routine Western medicine treatment and routine Western medicine treatment alone on $E/E'$ (SMD = 0.80, 95% CI –1.63 to 1.97, 206 participants). The result indicated that YQHX combined with conventional Western drugs group was no significantly better than conventional Western drugs group in the $E/E'$ and there was significant homogeneity among the 2 trials ($I^2 = 97\%$, $P < .00001$) (Fig. 16).

### 3.4.4. GRADE assessment.

Due to the poor methodology of the included studies and the obvious statistical heterogeneity among trials, quality of the evidence for all 5 outcomes (ORR, TCMSRR, BNP, NT-proBNP, LVEF) were “low” and “very low” according to the GRADE assessment (Table 3).

### 3.5. Publication bias

In order to detect possible publication bias, we analyzed the 13 trials that compared YQHX plus routine Western medicine treatment with routine Western medicine treatment alone in terms of the ORRs with a fixed effects model. The funnel plot of ORR was asymmetrical, indicating the presence of publication bias.
bias (Fig. 17). The detection of publication bias was not available for other outcomes as the included trials were <10.

4. Discussion

4.1. YQHX and CWM treatment in CHF has clinical efficacy

CHF is a serious end-stage of various heart diseases which have high morbidity and mortality. It is a clinical syndrome characterized by insufficient blood perfusion, abnormal distribution of peripheral blood flow, and activation of neuroendocrine.[2] Paroxysmal nocturnal dyspnea and edema are CHF's typical clinical features. High jugular pressure, apical beat, and rale of lung are typical signs. It is difficult to recover and easy to recur.[19] In terms of treatment, modern medicine has obvious advantages in the treatment of vasodilation, diuresis, and myocardial contractility; however, some patients with CHF have problems such as multiple organ damages, reduced tolerance of digitalis, hypotension, electrolyte disorder, and heavy economic burden due to the high cost of treatment.[19] The treatment effect is often unsatisfactory, which provides a broad application space for the treatment of CHF by combining traditional Chinese and Western medicine. The basic pathogenesis of TCM syndrome differentiation is Qi deficiency and blood stasis; the method of invigorating Qi and activating blood circulation (YQHX) is an important therapeutic principle of TCM in treating CHF. Results from previous studies showed that YQHX, as a complementary treatment, may improve the clinical symptoms, achieve the therapeutic effect, increase the exercise endurance, reduce the side effects of drugs, and increase the quality of life of CHF patients.[9,11,40] Hence, the combination of YQHX prescription and CWM treatment in CHF has attracted more clinical attention, and the related research literature is gradually increasing, which provides a reliable basis for discussing the application value and guiding clinical practice of integrated traditional Chinese and Western medicine treatment in CHF.

4.2. Summary of evidence

YQHX, as a complementary treatment, may improve ventricular function and the quality of life of CHF patients.

Figure 7. Forest plot of improvement of MLHFQ. MLHFQ = Minnesota Living with Heart Failure questionnaire.

Figure 8. Forest plot of improvement of 6MRR. 6MRR = 6-month readmission rate.
Nevertheless, the role of YQHX in the treatment of CHF is not fully clear. We aimed to provide the latest systematic review and meta-analysis to summarize the existing evidence of YQHX as an effective treatment for CHF. Unlike the previous meta-analysis, wherein the diagnosis was inappropriate due to outdated references hence the primary outcomes in the report were also inconsistent. With concerns on 19 trials, this meta-analysis about the ORR, TCMSRR showed that YQHX combined with CWM were more effective than CWM alone for CHF. Due to the poor methodological quality of the included trials and the insufficient number of trial participants, only limited evidence showed experimental group with YQHX may get better effect on natriuretic peptides (BNP or NT-proBNP), LEVF, TCMSS, 6MWT, MLHFQ, SV, 6MRR, and CRP, but the results had very significant heterogeneity. No significant differences were found between experimental groups and control groups on LVEDD and E/E'. At last, using of YQHX seemed safe and well tolerated for patients with CHF. In summary, although the strength of the evidence was low, we found potential effect of oral YQHX herbal preparations on improving some key symptoms in patients with CHF.

### 4.3. Possible explanations for the evidence

An important aim of treatment for CHF is to alleviate symptoms and improve well-being. According to this review, herbs or herbal prescriptions with the function of supplementing qi and activating blood circulation were commonly used to achieve this objective. Top 5 of most frequently used herbs were Huangqi (in 17 trials), Danshen (in 13 trials), Danggui (in 9 trials), Taoren (in 9 trials), and

---

**Figure 9.** Forest plot of improvement of 6MWT. 6MWT = 6-minute walk test.

**Figure 10.** Forest plot of improvement of BNP. BNP = B-type natriuretic peptide.
Chishao (in 8 trials). The modern pharmacological study confirmed that Huangqi could promote cell metabolism, improve the ability of myocardial hypoxia tolerance, reduce rennin-angiotensin and brain natriuretic peptide level, and improve heart function from many aspects.[42] Danshen has the function of antioxidation and improving disorders of microcirculation.[43] Danggui has the functions of antibacteria, antioxidation, and enhancing the immune function of the body.[44] Taoren has abilities of anticoagulant, antithrombotic, and hemodynamics effects.[45] Chishao has the functions of anticoagulant, antithrombotic, hypolipidemic, antiarteriosclerosis, and coronary artery dilation.[46] The 5 herbs have pharmacological effects on treating heart failure in several fields.
4.4. Limitations of the review

Low levels of evidence in this review were mainly caused by the poor quality and small sample size of originally included trials. Only 5 out of 19 trials reported on how the participants were randomly assigned to the intervention groups. The other trials simply mentioned “randomization,” with none of the trials indicating the use of allocation concealment and blinding. Three of the trials specified follow-ups. This study suggested that YQHX can effectively improve the cardiac function of patients with CHF, but the results had very significant heterogeneity. The inconsistency of findings of herbal medicine’s effect on improving main outcomes of CHF among these trials further reduced the internal validity of the evidence. Although we searched both Chinese and English databases, all of the included trials were retrieved from Chinese literature, which may have introduced potential selection bias and limited the external generalization of the evidence.
### Table 3
Summary of finding table of Yiqihuoxue formula with conventional Western medicine for patients diagnosed with CHF.

- **Patient:** Patients were diagnosed with CHF.
- **Settings:** Outpatient department/inpatient department.
- **Intervention:** Yiqihuoxue formula with conventional Western medicine.
- **Control:** Conventional Western medicine.

| Outcomes                  | Assumed risk | Corresponding risk | Relative effect (95% CI) | No. of participants (studies) | Quality of the evidence (GRADE) | Comments |
|---------------------------|--------------|--------------------|--------------------------|------------------------------|---------------------------------|----------|
| Overall response rate     | Control 786 per 1000 (954–999) | Yiqihuoxue 952 per 1000 (994–999) | RR 1.21 (1.15–1.27) | 1410 (13 studies) | Low* | Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. |
| TCM syndrome response rate| 727 per 1000 (814–986) | 901 per 1000 (974–996) | RR 1.24 (1.12–1.37) | 367 (4 studies) | Low* | Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. |
| BNP                       | The mean BNP in the intervention groups was 0.89 standard deviations lower (1.52–0.25 lower) | | SMD –0.89 | –1.52 to –0.25 (9 studies) | Very low* | Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. |
| NT-proBNP                 | The mean NT-proBNP in the intervention groups was 2.07 standard deviations lower (3.34–0.8 lower) | | SMD –2.07 | –3.34 to –0.8 (5 studies) | Very low* | Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. |
| LVEF                      | The mean LVEF in the intervention groups was 0.97 standard deviations higher (0.6–1.34 higher) | | SMD 0.97 | 0.6 to 1.34 (14 studies) | Low* | Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. |

Bold values indicate the results of GRADE.

* There were serious limitations of methodological quality of included trials according to the risk of bias assessment.

BNP = B-type natriuretic peptide, CHF = chronic heart failure, CI = confidence interval, LVEF = left ventricular ejection fraction, RR = risk ratio, SMD = standardized mean difference, TCM = traditional Chinese medicine.

**Figure 17.** Funnel plot of the overall response rate.
5. Conclusions

Due to the insufficient quality of trials that were analyzed, this review could not authenticate the effectiveness of YQHX in treating CHF at the present time. Purposefully designed trials with high methodological quality are needed to validate the effect of YQHX for patients with CHF. The results of the present systematic review will be disseminated to a variety of stakeholders interested in YQHX therapy to inform both the researchers for the further studies and clinical practice focused on CHF.

Authors contributions

Conceptualization: Miao Zhang.
Data curation: Ming-Yue Sun.
Formal analysis: Ming-Yue Sun.
Investigation: Ma Min, Zheng-Zhi Wu.
Methodology: Miao Zhang.
Project administration: Feng-Qin Xu.
Resources: Ming-Yue Sun.
Software: Miao Zhang.
Supervision: Ma Min, Zheng-Zhi Wu.
Validation: Yu Jin.
Visualization: Yu Jin.
Writing - original draft: Miao Zhang.
Writing - review & editing: Feng-Qin Xu.

References

[1] Gedela M, Khan M, Jonsson O. Heart failure. South Dakota Med. 2015;68:4030-7-9.
[2] Hoffman TM. Chronic heart failure. Pediatr Crit Care Med. 2016;17(Suppl 1):S119-123.
[3] Allida SM, Inglis SC, Davidson PM, et al. Thrust in chronic heart failure: a review. J Clin Nurs. 2015;24:916-9.
[4] Rogers C, Bush N. Heart failure: pathophysiology, diagnosis, medical treatment guidelines, and nursing management. Nurs Clin North Am. 2015;50:787-99.
[5] Chitnis AS, Aparasu RR, Chen H, et al. Effect of certain angioten- sin-converting enzyme inhibitors on mortality in heart failure: a multiple-propensity analysis. Res Soc Adm Pharm. 2012;8:145–56.
[6] Shi Q, Zhao H, Chen J, et al. Study on qi deficiency syndrome identi- fication modes of coronary heart disease based on metabolomic bio- markers. Evid Based Complement Altern Med. 2014;2014:281829.
[7] Wu H, Wang X, Gao S, et al. Yiqi-Huoxue granule (YQHX) down- regulates prothrombotic factors by modulating KLF2 and NF-xB in HUVECs following LPS stimulation. Oxid Med Cell Longevity. 2019;2019:9425183.
[8] Li H, Zhang Y, Ma J. Effects of yiqi huoxue compound combined with exercise therapy on MMP-1 and collagen type III expressions of cardiac muscle in chronic heart failure rats. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011;31:955–60.
[9] Lou LX, Wu AM, Zhang DM, et al. Yiqi Huoxue recipe improves heart function through inhibiting apoptosis related to endoplasmic reticulum stress in myocardial infarction model of rats. Evid Based Complement Altern Med. 2014;2014:749199.
[10] Ren W, Gao S, Zhang H, et al. Decomposing the mechanism of Qishen granules in the treatment of heart failure by a quantitative pathway analysis method. Molecules (Basel, Switzerland). 2018;23:1829.
[11] Li DP, Chen Q, Yi L. Effects of yiqi huoxue method on cardiac function in patients with congestive heart failure. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006;26:532-4.
[12] Campbell M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10:Ed000142.
[13] Flower A, Witt C, Liu JP, et al. Guidelines for randomised controlled trials investigating Chinese herbal medicine. J Ethnopharmacol. 2012;140:130-5.
[14] Palys KE, Berger VW. A note on the Jadad scale as an efficient tool for measuring trial quality. J Gastrointest Surg. 2013;17:1170-1.
[15] Zheng XY. Guidelines for Clinical Research on Chinese New Herbal Medicines. Beijing, China: China Medical Science Press. 2002:83-5.

[16] Borenstein M, Hedges LV, Higgins JP, et al. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97-111.
[17] Chen B, Benedetti A. Quantifying heterogeneity in individual partici- pant data meta-analysis with binary outcomes. Syst Rev. 2017;6:243.
[18] Jackson D. Discussion on quantifying publication bias in meta-analysis. Bioinformatics. 2018;74:793-6.
[19] Liu FW. Therapeutic effect and possible mechanism of Yiqi Huoxue Fang on chronic heart failure with qi deficiency and blood stasis. J Chin Med Mater. 2017;40:230-2.
[20] Ye YW, Guo FQ. Observation on effect of Yiqi Huoxue decoction in treatment of asymptomatic heart failure. Liaoning J Tradit Chinese Med. 2014;41:86-8.
[21] Tang S, Shen JF, Xu YH, et al. Effect of self-made Yiqi Huoxue formula in treatment of chronic heart failure of coronary heart disease and its action on the level of inflammatory factors. J Hebei TCM Pharmacol. 2018;33:11-4.
[22] Zhou SP, Liu SP. Effect of Yiqi Huoxue Lishui therapy on ejection fraction retaining heart failure. Med Innov China. 2018;15:139-42.
[23] Chen WT, Wang J, Xu XS, et al. Treatment of 118 cases of diastolic heart failure with “Yiqi Huoxue Fang”, Global Tradit Chinese Med. 2017;10:1351-4.
[24] He P. Observation of therapeutic effect of Yiqi Huoxue Lishui pre- scriptive on 80 cases of chronic heart failure. J Med Theory Pract. 2018;31:2405-6.
[25] Wang KZ, Li X. Effect of Yiqi Huoxue decoction on TCM syndrome and quality of life in patients with chronic heart failure due to Qi defi- ciency and blood stasis. ShaanXi Tradit Chinese Med. 2018;39:32-4.
[26] Yu GZ, Zhang YW, Jia ZK, et al. Clinical study on treatment of heart failure (Qi Deficiency and Blood Stasis Syndrome) with Yiqi Huoxue Method. J Clin Med. 2018;5:73-6.
[27] He PG, Liu Q, Feng XH, et al. Clinical efficacy and quality of life eval- uation of Zhigancao decoction, Xuefu Zhuyu decoction and western medicine in the treatment of chronic heart failure (qi and yin defi- ciency and blood stasis). Pharmacol Clin Chinese Materia Medica. 2019;35:168–72.
[28] Yang J. Effect of Yiqi Huoxue Lishui recipe combined with western medicine on heart function and serum NT-proBNP level in patients with chronic heart failure. J Community Med. 2017;15:76-7.
[29] Li HL, Zhang KQ, Effect of Shenqi Fumai decoction combination with western medicine on chronic heart failure and its influence on cardiac function. ShaanXi Tradit Chinese Med. 2018;40:163-6.
[30] Liu H, Liu J, Ding XH, et al. Effect of Yiqi Huoxue herbal medicine combined with western medicine on elderly patients with chronic heart failure and the effect on quality of life. Jilin J Chinese Med. 2017;37:781–3.
[31] Qian SQ, Xu WL, Xu ZL. Effect of Yiqi Huoxue Qiangxin recipe on cardiac function and myocardial remodeling in patients with chronic heart failure and Qi deficiency and blood stasis type. Chinese J Tradit Med Sci Technol. 2018;25:66-8.
[32] Wang DL, Wang XF. Clinical observation on treatment of chronic heart failure with Yiqi Huoxue Huayu Tongluo method. Xinjiang J Tradit Chinese Med. 2015;33:9-11.
[33] Wang XL, Chen WG. Clinical effect of integrated traditional Chinese and western medicine in the treatment of chronic heart failure of coro- norary heart disease with Qi deficiency and blood stasis type. Chin J Pract. 2019;9:143-4.
[34] Feng XX. Flavored Yang five soup also supplement in qi deficiency and blood stasis type of chronic heart failure: the NT-proBNP affect clinical research. Chin J Ethnomed Ethnopharm. 2013;12:39-43.
[35] Li XX. Randomized parallel controlled study of Yiqi Huoxue Huayu decoction combined with Western Medicine on chronic heart failure (qi deficiency and blood stasis). J Pract Tradit Chinese Int Med. 2019;33:2-4.
[36] Zhang YG, Wang JX. Buyang Huanwu decoction combined with western medicine classification for chronic heart failure (Qi deficiency and blood stasis) randomized parallel controlled study. J Pract Tradit Chinese Int Med. 2018;31:2405-6.
[37] Zhang YY, Feng ZQ. Clinical curative effect of Yiqi huoxue herbs for chronic heart failure and analysis on prognosis. Liaoning J Tradit Chinese Med. 2014;44:193–5.
[38] Mareev YV, Mareev YV. Characteristics and treatment of hospitalized patients with CHF. Kardiozologia. 2017;57:20-30.
[39] Bhart KN, Butler J. Myocardial energetics and heart failure: a review of recent therapeutic trials. Curr Heart Fail Rep. 2018;15:191-7.
[40] Du WT, Ming G, Liu P, et al. Treatment of chronic heart failure with carotid plaque patients by Yiqi Huoxue Tongyang Xezhuo recipe. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015;35:1322–5.
[41] Lewis EF, Lamas GA, O’Meara E, et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. 2007;9:83–91.

[42] Shan H, Zheng X, Li M. The effects of Astragalus membranaceus active extracts on autophagy-related diseases. Int J Mol Sci. 2019;20:1904.

[43] Xu J, Wei K, Zhang G, et al. Ethnopharmacology, phytochemistry, and pharmacology of Chinese Salvia species: a review. J Ethnopharmacol. 2018;225:18–30.

[44] Ma J, Huang J, Hua S, et al. The ethnopharmacology, phytochemistry and pharmacology of Angelica biserrata—a review. J Ethnopharmacol. 2019;231:152–69.

[45] Xi S, Qian L, Tong H, et al. Toxicity and clinical reasonable application of Taoren (Semen Persicae) based on ancient and modern literature research. J Tradit Chin Med. 2013;33:272–9.

[46] Zhang JJ, Li W, Wang LL, et al. Varieties, functions and clinical applications of Chishao and Baishao: a literature review. Zhongguo Zhong Yao Za Zhi. 2013;38:3595–601.